Feasibility and acceptability of FinCare: A personalized online tool for estimating out-of-pocket costs for cancer treatment - Top-Institutions - MDSpire

Feasibility and acceptability of FinCare: A personalized online tool for estimating out-of-pocket costs for cancer treatment

  • By

  • Carolyn Y. Fang

  • Amani Boudriga

  • Amine Raounak

  • Howard Isenstein

  • Brian L. Egleston

  • Erin Tagai

  • Melissa McShane

  • Efrat Dotan

  • Daniel M. Geynisman

  • July 14, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    American Cancer Society
    American Cancer Society

    Atlanta, Georgia

    Key Differentiators

    • Oncology

  • #3

    Fred Hutchinson Cancer Research Center
    Fred Hutchinson Cancer Research Center

    Seattle, Washington

    Key Differentiators

    • Oncology

  • #4

    Seattle Cancer Care Alliance
    Seattle Cancer Care Alliance

    Seattle, Washington

    Key Differentiators

    • Oncology

  • #5

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

    Key Differentiators

    • Oncology

Original Source(s)

Feasibility and acceptability of FinCare: A personalized online tool for estimating out-of-pocket costs for cancer treatment

  • by Carolyn Y. Fang, Amani Boudriga, Amine Raounak, Howard Isenstein, Brian L. Egleston, Erin Tagai, Melissa McShane, Efrat Dotan, Daniel M. Geynisman

  • July 14, 2026

Related Content

A hybrid ViT-L/32–MaxViT-L architecture with adaptive gated fusion for multiclass gastrointestinal disease detection and multi-method post-hoc explainability

Circular RNA circEVI5 functions as a miR-433 sponge to promote renal cell carcinoma progression via GBP2-mediated oncogenic signaling

Consolidative versus salvage stereotactic ablative radiotherapy to the primary lung tumor in stage IV non–small cell lung cancer